Carcinoma, ovarian epithelial, occurs in women of all races and with all age groups. The most common primary site is the ovary, but carcinoma, ovarian epithelial, also occurs in the fallopian tubes, peritoneum, adrenal gland, uterus, and intestine.
Ovarian carcinoma consists of tumors derived from the ovarian theca (endothelial) layer. In about 90% of cases, the tumor is solid and tends to metastasize to distant sites rather than regional lymph nodes. The overall 5-year survival was 38%. Epithelial serous and endometrioid tumors have significantly better survival to the time of disease recurrence compared to clear cell tumors, however this finding is dependent on the stage and response rates of cancer.
We can summarize our findings as follows: (1) the primary tumor remains an incurable disease, (2) the initial, curative treatment is a surgery without adjuvant chemotherapy, (3) recurrence of the tumor after surgery is rare, and (4) ovarian epithelial cancer is not a curable disease.
Data from a recent study reinforces the hypothesis that ovarian carcinoma has one primary site of origin, and that this origin is not associated with smoking or ovarian cysts. Ovarian carcinoma, especially its serous phenotype, occurs at an increased rate in women over the age of 45 years.
Chemotherapy is widely used, particularly in recurrent carcinoma. Tissue preservation and cytoreductive surgery are not a common treatment, with the main focus being on minimizing the impact of the cancer. Radiation therapy is rarely involved, except in the treatment of recurrent disease.
The symptoms of carcinoma, ovarian epithelial are diverse. Ovarian carcinoma often presents as abdominal pain because it produces large amounts of CA-125. However, this does not always occur due to other causes and the presence of pain and CA-125 levels should be obtained cautiously before deciding surgery is needed. The presence of CA-125 with a palpable lesion is one of the highest risk factors for ovarian neoplasia.
In a recent study, findings suggests that bevacizumab improves both QOL and QLQ-CX items for patients with carcinoma, ovarian epithelial compared to those without bevacizumab. In a recent study, findings suggest that bevacizumab treatment might improve QOL in patients with carcinoma, ovarian epithelial.
Patients with carcinoma are more likely to have lymphatic and hematogenous spread in the ovarian epithelial component compared to patients with ovarian stromal sarcoma. The incidence of lymphatic, and hematogenous spread increases in the presence of a component of ovarian epithelial sarcoma and in the presence of nodal or distant metastases.
There are no clear recommendations to facilitate informed, evidence-based decisions regarding clinical trials for carcinoma, ovarian epithelia. We should consider patients in the age of 40-80 years, women in the age of 55 years with FIGO stage 1-2 of high grade non-epithelial malignancy and BRCA carriers.
The mean age was 59.3 yr (SD 15 yr.)<br>About half of these patients were symptomatic. About 9% died before or during surgery. About 1 in 25 were diagnosed with multiple masses.<br>The 5 yr. Survival rate was 67%. Survivors included those without the BRCA1 mutation but with other defects in DNA repair genes.